Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4874699
Max Phase: Preclinical
Molecular Formula: C61H106N18O15
Molecular Weight: 1331.63
Molecule Type: Unknown
Associated Items:
ID: ALA4874699
Max Phase: Preclinical
Molecular Formula: C61H106N18O15
Molecular Weight: 1331.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O)[C@H](C)OC(=O)[C@@H](N)CCC(N)=O
Standard InChI: InChI=1S/C61H106N18O15/c1-7-34(4)13-11-12-16-48(82)70-39(19-25-62)55(87)79-50(36(6)94-61(93)38(67)17-18-47(68)81)60(92)75-42(22-28-65)52(84)74-44-24-30-69-59(91)49(35(5)80)78-56(88)43(23-29-66)72-51(83)40(20-26-63)73-57(89)45(31-33(2)3)76-58(90)46(32-37-14-9-8-10-15-37)77-53(85)41(21-27-64)71-54(44)86/h8-10,14-15,33-36,38-46,49-50,80H,7,11-13,16-32,62-67H2,1-6H3,(H2,68,81)(H,69,91)(H,70,82)(H,71,86)(H,72,83)(H,73,89)(H,74,84)(H,75,92)(H,76,90)(H,77,85)(H,78,88)(H,79,87)/t34-,35+,36-,38-,39-,40-,41-,42-,43-,44-,45-,46+,49-,50-/m0/s1
Standard InChI Key: UPZVFCJFEJGVSF-PKONEQLISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1331.63 | Molecular Weight (Monoisotopic): 1330.8085 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Li J, Guan D, Chen F, Shi W, Lan L, Huang W.. (2021) Total and Semisyntheses of Polymyxin Analogues with 2-Thr or 10-Thr Modifications to Decipher the Structure-Activity Relationship and Improve the Antibacterial Activity., 64 (9.0): [PMID:33909428] [10.1021/acs.jmedchem.0c02217] |
Source(1):